These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 21830453)
1. Treatment of ovarian hyperstimulation syndrome: new insights. Kasum M; Oresković S Acta Clin Croat; 2010 Dec; 49(4):421-7. PubMed ID: 21830453 [TBL] [Abstract][Full Text] [Related]
2. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Chen SU; Chou CH; Lin CW; Lee H; Wu JC; Lu HF; Chen CD; Yang YS Hum Reprod; 2010 Mar; 25(3):757-67. PubMed ID: 20008399 [TBL] [Abstract][Full Text] [Related]
3. New insights in prediction of ovarian hyperstimulation syndrome. Kasum M; Oresković S Acta Clin Croat; 2011 Jun; 50(2):281-8. PubMed ID: 22263397 [TBL] [Abstract][Full Text] [Related]
10. Prevention and management of ovarian hyperstimulation syndrome. Vlahos NF; Gregoriou O Ann N Y Acad Sci; 2006 Dec; 1092():247-64. PubMed ID: 17308149 [TBL] [Abstract][Full Text] [Related]
11. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964 [TBL] [Abstract][Full Text] [Related]
12. New insights in mechanisms for development of ovarian hyperstimulation syndrome. Kasum M Coll Antropol; 2010 Sep; 34(3):1139-43. PubMed ID: 20977119 [TBL] [Abstract][Full Text] [Related]
13. Identification of the high-risk patient for ovarian hyperstimulation syndrome. Papanikolaou EG; Humaidan P; Polyzos NP; Tarlatzis B Semin Reprod Med; 2010 Nov; 28(6):458-62. PubMed ID: 21082503 [TBL] [Abstract][Full Text] [Related]
16. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor response to exogenous chorionic gonadotropic hormone in the luteal phase of women with a history of severe ovarian hyperstimulation syndrome. Griesinger G; Dafopoulos K; Schultze-Mosgau A; Jelkmann W; von Otte S; Diesing D; Diedrich K Arch Gynecol Obstet; 2006 Apr; 274(1):29-33. PubMed ID: 16408189 [TBL] [Abstract][Full Text] [Related]
18. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome. Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536 [TBL] [Abstract][Full Text] [Related]
19. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review. Kalampokas T; Creatsas G; Kalampokas E Gynecol Endocrinol; 2013 Feb; 29(2):98-100. PubMed ID: 23110560 [TBL] [Abstract][Full Text] [Related]
20. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Villasante A; Pacheco A; Pau E; Ruiz A; Pellicer A; Garcia-Velasco JA Hum Reprod; 2008 Mar; 23(3):662-7. PubMed ID: 18216038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]